Arcus Biosciences Inc (NYSE:RCUS)
$ 15.27 -0.56 (-3.54%) Market Cap: 1.40 Bil Enterprise Value: 417.63 Mil PE Ratio: 0 PB Ratio: 2.47 GF Score: 79/100

Arcus Biosciences to Discuss the Expanded Partnership with Gilead Sciences Inc- Conference Call Transcript

Nov 18, 2021 / 01:00PM GMT
Release Date Price: $43.54 (+17.96%)
Operator

Hello all. I would like to welcome you to the Arcus Biosciences Corporate Update Call. My name is Brika, and I'll be today's event specialist. (Operator Instructions)

I would now like to hand the call over to your host, Holli. So Holli, please go ahead.

Holli Kolkey
Arcus Biosciences, Inc. - VP of Corporate Communications

Good morning, everyone. Thank you, Brika. Thank you all for participating in today's call to discuss our announcement this morning regarding Gilead's early option exercises. Joining me from Arcus are Terry Rosen, Chief Executive Officer; Juan Jaen, President; Jennifer Jarrett, Chief Operating Officer; Bob Goeltz, Chief Financial Officer; and Kartik Krishnan, Chief Medical Officer.

I'd like to remind you that on the call, management will make forward-looking statements within the meaning of securities law's safe harbor provision. For example, statements about our future clinical development plans and data releases as well as any anticipated benefits of the transaction. All statements other than historical facts involve risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot